Pro Medicus Ltd (ASX: PME) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Pro Medicus Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $13.33 billion
P/E Ratio 48.23
Dividend Yield 0.51%
Shares Outstanding 104.47 million
Earnings per share 2.243
Dividend per share 0.64
Year To Date Return -47.80%
Earnings Yield 2.07%
Franking 100%
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Pro Medicus Ltd (ASX: PME)
    Latest News

    Shot of a young scientist using a digital tablet while working in a lab.
    Share Market News

    Up 160% in a year, why this ASX 200 healthcare stock is surging again today

    Pro Medicus Limited (ASX: PME) shares are having a good start to the session. In morning trade, the ASX 200…

    Read more »

    Happy couple receiving key to apartment.
    Share Market News

    Best ASX 200 shares vs. best suburbs for property investment in 2024

    Let's get specific about which stocks and suburban property markets delivered the best capital growth.

    Read more »

    Medical or healthcare workers grasp hands in the universal expression of teamwork
    Healthcare Shares

    Here's how the ASX 200 market sectors stacked up last week

    Healthcare was the strongest sector last week, with market darling Pro Medicus surging yet again.

    Read more »

    Three happy team mates holding the winners trophy.
    Best Shares

    Which ASX 200 large-cap shares outperformed their peers in 2024?

    We reveal the 16 best ASX 200 large-cap stocks for share price growth last year.

    Read more »

    A young woman slumped in her chair while looking at her laptop.
    Share Market News

    Here are the top 10 ASX 200 shares today

    Investors pulled back today after a strong week thus far.

    Read more »

    A group of people at a party look upwards to the camera as they celebrate the rise of ASX value shares
    Share Gainers

    16 ASX shares that doubled in value last year

    There were multiple ASX All Ords stocks that delivered double-or-more share price growth in 2024.

    Read more »

    A businessman compares the growth trajectory of property versus shares.
    Share Market News

    Shares vs. property: Which investment delivered the best capital growth in 2024?

    Where did home values rise by almost 20%? And which ASX 200 stock more than tripled in value?

    Read more »

    A man has a surprised and relieved expression on his face.
    Technology Shares

    Pro Medicus shares rocketed 161% in 2024: Is it still a buy?

    Let's see whether analysts think this high-flying stock can keep rising.

    Read more »

    Portrait, confidence and team of doctors in the hospital standing after a consultation or surgery. Success, healthcare and group of professional medical workers in collaboration at a medicare clinic.
    Healthcare Shares

    Healthy gains: 5 best ASX 200 healthcare shares of 2024

    Four of the five best-performing ASX 200 healthcare stocks of 2024 more than doubled in value.

    Read more »

    A happy young couple lie on a wooden deck using a skateboard for a pillow.
    Broker Notes

    Top brokers name 3 ASX shares to buy next week

    Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

    Read more »

    a man in a business suite throws his arms open wide above his head and raises his face with his mouth open in celebration in front of a background of an illuminated board tracking stock market movements.
    Broker Notes

    Brokers name 3 ASX shares to buy today

    Here's why brokers are feeling bullish about these three shares.

    Read more »

    Multiracial happy young people stacking hands outside - University students hugging in college campus - Youth community concept with guys and girls standing together supporting each other.
    Share Gainers

    These were the 5 best performing ASX 200 shares in 2024

    Let's see why these shares delivered massive returns last year.

    Read more »

    Frequently Asked Questions

    Yes, the company historically pays two fully franked dividends a year. 

    Pro Medicus generally pays its shareholder dividends in March and October.

    Pro Medicus Ltd listed on the ASX on 10 October 2000.

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    03 Sep 2025 $0.3000 100.00% Final 25 Sep 2025
    27 Feb 2025 $0.2500 100.00% Interim 21 Mar 2025
    04 Sep 2024 $0.2200 100.00% Final 26 Sep 2024
    29 Feb 2024 $0.1800 100.00% Interim 22 Mar 2024
    06 Sep 2023 $0.1700 100.00% Final 28 Sep 2023
    02 Mar 2023 $0.1300 100.00% Interim 24 Mar 2023
    08 Sep 2022 $0.1200 100.00% Final 30 Sep 2022
    03 Mar 2022 $0.1000 100.00% Interim 25 Mar 2022
    09 Sep 2021 $0.0800 100.00% Final 01 Oct 2021
    04 Mar 2021 $0.0700 100.00% Interim 19 Mar 2021
    10 Sep 2020 $0.0600 100.00% Final 02 Oct 2020
    05 Mar 2020 $0.0600 100.00% Interim 20 Mar 2020
    12 Sep 2019 $0.0450 100.00% Final 04 Oct 2019
    12 Mar 2019 $0.0250 100.00% Special Cash 17 May 2019
    07 Mar 2019 $0.0350 100.00% Interim 22 Mar 2019
    06 Sep 2018 $0.0350 100.00% Final 27 Sep 2018
    08 Mar 2018 $0.0250 100.00% Interim 23 Mar 2018
    07 Sep 2017 $0.0000 100.00% Final 28 Sep 2017
    08 Sep 2016 $0.0150 0.00% Final 29 Sep 2016
    10 Mar 2016 $0.0150 0.00% Interim 24 Mar 2016
    15 Mar 2006 $0.0050 100.00% Special 05 Apr 2006
    15 Mar 2006 $0.0200 100.00% Interim 05 Apr 2006
    14 Sep 2005 $0.0050 100.00% Special Cash 04 Oct 2005
    14 Sep 2005 $0.0275 100.00% Final 04 Oct 2005
    16 Mar 2004 $0.0125 100.00% Interim 05 Apr 2004

    PME ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Pro Medicus Ltd

    Pro Medicus Ltd (ASX: PME) is a provider of medical imaging technology globally. The company is recognised as a leading supplier of radiology information systems (RIS), picture archiving and communication systems (PACS), and advanced visualisation solutions for medical practices and hospitals.

    Pro Medicus's RIS technology products also include medical accounting, clinical reporting, appointments/scheduling, and marketing/management applications. The company's services to the imaging sector cover workflow mapping and optimisation, network design and implementation, hardware sourcing and configuration, and staff and management training.

    Pro Medicus has offices in Australia, Germany, and the US with its products adopted by many top-tier hospitals and health facilities, particularly in the US market.

    PME Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    26 Feb 2026 $127.60 $11.37 9.78% 795,477 $120.10 $127.67 $120.10
    25 Feb 2026 $116.23 $8.08 7.47% 601,935 $109.91 $116.23 $108.60
    24 Feb 2026 $108.15 $-7.15 -6.20% 783,400 $111.99 $114.34 $107.75
    23 Feb 2026 $115.30 $-11.21 -8.86% 517,235 $127.08 $127.58 $115.30
    20 Feb 2026 $126.51 $-2.65 -2.05% 510,902 $128.88 $129.49 $123.36
    19 Feb 2026 $129.16 $6.16 5.01% 653,806 $124.64 $129.78 $121.51
    18 Feb 2026 $123.00 $-2.96 -2.35% 758,014 $125.50 $130.00 $122.21
    17 Feb 2026 $125.96 $8.99 7.69% 757,291 $117.42 $127.55 $116.98
    16 Feb 2026 $116.97 $-1.25 -1.06% 769,492 $118.30 $121.32 $113.67
    13 Feb 2026 $118.22 $-10.78 -8.36% 1,455,798 $126.95 $128.90 $118.22
    12 Feb 2026 $129.00 $-40.47 -23.88% 1,129,492 $152.48 $152.48 $129.00
    11 Feb 2026 $169.47 $1.81 1.08% 283,625 $165.00 $169.56 $163.50
    10 Feb 2026 $167.66 $6.49 4.03% 200,701 $163.00 $167.66 $161.79
    09 Feb 2026 $161.17 $3.55 2.25% 482,202 $162.00 $162.90 $159.30
    06 Feb 2026 $157.62 $-7.31 -4.43% 325,920 $161.60 $162.07 $155.63
    05 Feb 2026 $164.93 $-1.42 -0.85% 399,506 $166.35 $168.48 $163.39
    04 Feb 2026 $166.35 $-11.21 -6.31% 471,636 $167.88 $170.00 $162.19
    03 Feb 2026 $177.56 $-0.59 -0.33% 265,894 $178.15 $179.26 $175.39
    02 Feb 2026 $178.15 $-5.97 -3.24% 264,631 $182.00 $182.00 $175.48
    30 Jan 2026 $184.12 $2.43 1.34% 313,605 $181.27 $185.13 $178.84
    29 Jan 2026 $181.69 $-4.59 -2.46% 371,211 $187.08 $187.27 $178.61
    28 Jan 2026 $186.28 $-3.89 -2.05% 320,367 $194.00 $194.85 $184.32

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    26 Feb 2026 Anthony Hall Buy 8,146 $993,812
    On-market trade.
    25 Feb 2026 Anthony Hall Buy 9,000 $1,029,690
    On-market trade.
    24 Feb 2026 Sam Hupert Buy 4,500 $489,240
    On-market trade.
    24 Feb 2026 Anthony Hall Buy 8,500 $936,105
    On-market trade.
    23 Feb 2026 Peter Kempen Buy 400 $46,572
    On-market trade.
    13 Feb 2026 Deena Shiff Buy 788 $99,815
    On-market trade.
    13 Feb 2026 Anthony Glenning Buy 2,080 $249,204
    On-market trade.
    29 Dec 2025 Peter Kempen Buy 600 $134,400
    On-market trade. As per announcement - 30/12/2025
    23 Dec 2025 Sam Hupert Buy 2,250 $499,477
    On-market trade.
    23 Dec 2025 Anthony Hall Buy 2,270 $500,103
    On-market trade.
    22 Dec 2025 Sam Hupert Buy 2,250 $498,262
    On-market trade.
    22 Dec 2025 Anthony Hall Buy 2,250 $499,275
    On-market trade.
    03 Sep 2025 Sam Hupert Transfer 50,000 $14,950,000
    Off-market transfer. Estimated value
    12 Mar 2025 Anthony Glenning Buy 50 $10,979
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Sam Aaron Hupert Chief Executive OfficerManaging Director Oct 2007
    Mr Hupert, left general practice in late 1984 to devote himself full time to managing the Group. Sam served as CEO from the time he co-founded the company until October 2007 at which time he stepped down to become an executive director. Sam resumed full time CEO activities in October of 2010.
    Mr Anthony Barry Hall Executive DirectorTechnology Director Jan 1983
    Mr Hall has been principal architect and developer of the core software systems that underpin Visage RIS.
    Mr Peter Terence Kempen Non-Executive ChairmanNon-Executive Director Mar 2008
    Mr Kempen is Chairman of Australasian Leukemia and Lymphoma Group. He is also a Trustee of the Barr Family Foundation and a member of the Boards of St Hilda's College Ltd, University of Melbourne, and the Olivia Newton-John Cancer Research Institute. Peter has previously been Chairman of Patties Food Limited, Chairman of Danks Holdings Limited, Chairman of Ivanhoe Grammar School and Managing Partner of Ernst & Young Corporate Finance Australia. Peter was appointed a Member in the General Division of the Order of Australia (AM) in the 2018 Queen's Birthday Honors. He became Chairman in August 2010 before which he served as a Non-Executive Director of the Company.
    Ms Alice Joan Morrice Williams Non-Executive Director Sep 2021
    Ms Williams is also a non-executive director of Vocus Group, Swimming Australia, Australian Submarine Corporation (ASC Pty Ltd) and Mercer Investments Australia Ltd. She is chair of the Audit & Risk Committee of ASC and Vocus Group and is a member of the Audit & Risk Committee and Due Diligence Committee of Mercer Investments (Australia) Ltd. Alice holds other board positions with Tobacco Free Portfolios and is on the Advisory Council of the Florey Institute of Neuroscience Novell Project. Previous board roles include Director and Chair of the Audit Committee of Cooper Energy, Djerriwarrh Investments, Chair of Nomination, Remuneration and Human Resources Committee and Non-Executive Director of Equity Trustees Ltd, and Nonexecutive member of the Foreign Investment Review Board. Alice is Chair of the Risk committee and serves on the People & Culture committee.
    Ms Deena Robyn Shiff Non-Executive Director Aug 2020
    Ms Shiff is an Independent Board Member of the Global Alliance for Vaccines and Immunization, the multi-lateral global health fund based in Geneva, the Chairman of AROSE (Australian Remote Operations in Space and Earth), and since July 2025, the Chairman of the Australian Telecommunications Alliance. and Chairman of the Care Economy Co Operative Research Centre. She also chairs the International Advisory Board of the Australian Research Centre of Excellence on Automated Decision Making and Society. Deena is Chair of the People & Culture committee and serves on the Risk committee.
    Mr Anthony James Glenning Non-Executive Director May 2016
    Mr Glenning is a fund adviser to Skalata Ventures, investing in early-stage companies to help them scale and grow into sustainable businesses. Anthony has previously been an Investment Director at Starfish Ventures and was the founder and CEO of Tonic Systems and a founding Non-Executive Director of Cameron Systems. He has also held senior software engineering positions at Google and Sun Microsystems Inc. Anthony also serves on the People & Culture committee and Risk committee.
    Dr Leigh Bernard Farrell Non-Executive Director Sep 2017
    Dr Farrell is the Managing Director of AdNED Pty Ltd, non-executive director of both Ena Respiratory Pty Ltd and Axelia Oncology Pty Ltd, a member of the Walter and Eliza Hall Institute of Medical Research Board Commercialization Committee, a member of the Scientific and Industry Advisory Committee of the Australian Research Council Centre for Cryo-electron Microscopy of Membrane Proteins and a member of the Investment Committee for the CUREAtor Plus.Dementia and Cognitive Decline Grants which is funded by the Australian Medical Research Future Fund. Leigh was previously Head of Health Security Systems Australia, a Division of DMTC Ltd, Senior Vice President, Commercial of Certara USA, Inc. where he was responsible for Asia Pacific Commercial. Prior to this, he was Chairman and COO of d3 Medicine LLC, which was acquired by Certara USA, Inc. Leigh also serves on the People & Culture committee and Risk committee.
    Ms Danny English Company Secretary Mar 2023
    -
    Clayton Hatch Chief Financial Officer
    -
    Danny English Company Secretary
    -
    Malte Westerhoff General Manager Europe and Global Chief Technology Officer
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Mr A Hall (multiple shareholdings) 24,144,000 23.11%
    Dr S Hupert (multiple shareholdings) 24,137,660 23.11%
    HSBC Custody Nominees (Australia) Limited 23,739,921 22.73%
    J P Morgan Nominees Australia Limited 7,952,739 7.61%
    Citicorp Nominees Pty Ltd 7,726,022 7.40%
    BNP Paribas Noms Pty Ltd 1,781,046 1.70%
    Mr Peter Terence Kempen & Mrs Elaine Margaret Kempen multiple shareholdings) 629,082 0.60%
    Mr Michael Wu 439,242 0.42%
    Grain Exporters (Australia) Pty Ltd 437,925 0.42%
    National Nominees Limited 402,482 0.39%
    Netwealth Investments Limited 297,897 0.29%
    Mr Stephen Geoffrey Wilson & Ms Denise Adele Prandi 281,417 0.27%
    Mr Colin Gregory Organ 271,000 0.26%
    Mr John Charles Plummer 250,000 0.24%
    Mr Danny Tauber 164,007 0.16%
    Mr Bram Vander Jagt & Mrs Maaike Vander Jagt 140,000 0.13%
    Mr Sean Michael Lambright 127,587 0.12%
    A Haig Retirement Manager Pty Ltd 114,723 0.11%
    Mr Kenneth John Vander Jagt & Mrs Tanya Vander Jagt 103,000 0.10%
    BNP Paribas Noms (Nz) Ltd 90,680 0.09%

    Profile

    since

    Note